Analyst Price Targets — ACIU
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 13, 2026 1:05 pm | Lucy Codrington | Jefferies | $7.00 | $3.01 | StreetInsider | Jefferies Reiterates Buy Rating on AC Immune SA (ACIU): '2025 financials largely immaterial' |
| May 30, 2024 4:49 pm | Thomas Shrader | BTIG | $8.00 | $3.97 | TheFly | AC Immune initiated with a Buy at BTIG |
| July 11, 2022 6:52 am | — | Leerink Partners | $10.00 | $3.35 | Benzinga | SVB Leerink Maintains Outperform on AC Immune, Lowers Price Target to $10 |
Latest News for ACIU
AC Immune stock gains after expansion of its agreement with LLY, adding next-generation Tau Morphomer candidates and boosting long-term Alzheimer's strategy.
Here is how AC Immune (ACIU) and Assertio (ASRT) have performed compared to their sector so far this year.
This will help fund the biotech's development of a unique treatment for neurodegenerative diseases like Alzheimer's. The company could earn more than $2.1 billion if this work is successful.
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for targeting intracellular Tau and significant progress made with our Morphomer small molecules Investigational New Drug (IND)-enabling studies to commence in H1 2026 Lausanne, Switzerland, April 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage…
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ACIU.
U.S. House Trading
No House trades found for ACIU.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.